Abstract:Joana Hygino, 1, &ast Marisa C Sales, 2, &ast Priscila M Sacramento, 1 Taissa M Kasahara, 3 Júlio César Costa da Silva, 3 Rafaela Bilhão, 3 Regis M Andrade, 4 Cláudia Cristina Ferreira Vasconcelos, 1 Cleonice AM Bento 1, 3– 5 1 Post-Graduate Program in Neurology, Federal University of the State of Rio de Janeiro, Rio de Janeiro City, Brazil; 2 Post-Graduate Program in Microbiology, University of the State of Rio de Janeiro, Rio de Janeiro City, Brazil; 3 Post-graduate Program in Molecular and Cellular Biology, Federal University of the State of Rio de Janeiro, Rio de Janeiro City, Brazil; 4 Department of General Medicine, Federal University of the State of Rio de Janeiro, Rio de Janeiro City, Brazil; 5 Department of Microbiology and Parasitology, Federal University of the State of Rio de Janeiro, Rio de Janeiro City, Brazil &astThese authors contributed equally to this work Correspondence: Cleonice AM Bento, Department of Microbiology and Parasitology, Federal University of the State of Rio de Janeiro, Frei Caneca 94, 20.261-040, Rio de Janeiro, RJ, Brazil, Tel/Fax + 55-21-2531-7906, Email Purpose: The presence of T cells expressing TLR-2 and TLR-4 has been associated with relapsing-remitting multiple sclerosis (RRMS) pathogenesis. Here, we evaluated whether the effectiveness of DMT in controlling clinical activity of the disease would be associated with modulation of proportion of TLRs + T cells. Patients and Methods: Whole peripheral blood mononuclear cells, purified CD4 + and CD8 + T cells from RRMS patients were cultured with different stimuli. The frequency of IL-17-secreting CD4 + and CD8 + T cells positive for TLR-2 and TLR-4 was determined by flow cytometry. The cytokine profile of these T cells following TLR-2 and TLR-4 stimulation was determined by Multiplex. Some of these T cell cultures were treated with hydrocortisone. The levels of LPS-binding protein (LBP) were dosed by ELISA. Clinical (occurrence of relapses) and radiological (number of active brain lesions) activity were evaluated during the 1-year follow-up. Results: Despite DMT, high intensity of TLR-2 and TLR-4 expression on (CD4 + and CD8 + ) T-cells, as well as the frequency of IL-17-secreting (CD4 + and CD8 + ) T-cells, are predictive of future RRMS relapses. Moreover, higher cytokine production related to Th17/Tc-17 phenotypes in response to TLR-2 and TLR-4 agonists was observed in DMT-treated patients and displayed an elevated number of brain lesions. The hyperresponsiveness of MS-derived T-cells to TLR-2 and TLR-4 ligands, with high levels of IL-1β, IL-6, IL-17, IFN-γ and GM-CSF in response to both TLR agonists, positively correlated with plasma LBP levels. Interestingly, corticoid was less efficient in reducing Th17 and Tc-17 cytokine production induced by TLR-2 and TLR-4 ligands in DMT-treated patients who relapsed during follow-up. Conclusion: Collectively, the data suggested that persistence of circulating Th17 and Tc17 cells expressing elevated levels of functional TLR-2 and TLR-4 could indicate high disease activity and lower therapeutic efficacy in RRMS patients. Keywords: multiple sclerosis, toll-like receptors, T cells, Th17, LPS-binding protein Most patients with multiple sclerosis (MS) suffer from recurrent autoimmune attacks on the myelin sheath of the central nervous system (CNS), coordinated by different cytokines released from effector T-cell subsets, followed by clinical remission. 1 Recurrent acute inflammatory flare-ups can affect any area of the CNS, leading to sensory, autonomic, cognitive, and motor function deficits. 2,3 While acute relapses are commonly treated with corticosteroid, another group of immunomodulatory drugs, named disease-modifying therapies (DMTs), are used to try to reduce the frequency and severity of bouts. 4,5 In RRMS, most frequently prescribed DMT classes mainly targeting memory and activated T cells by different mechanisms. 5,6 Unfortunately, over time, even under DMTs, remission periods become less marked and the majority of relapsing-remitting MS (RRMS) patients progress to a more neurodegenerative form, named secondary progressive MS (SPMS). The risk of disease progression has been mainly observed among RRMS patients with high disease activity, that is characterized by frequent relapses, higher number of brain lesions, and/or deterioration of neurological function during the observation period (1 to 4 years), despite DMT. 7,8 Probably, adverse events that enhance cytokine pro -Abstract Truncated-

Major depression favors the expansion of Th17-like cells and decrease the proportion of CD39+Treg cell subsets in response to myelin antigen in multiple sclerosis patients

Hyperresponsiveness of Corticoid-Resistant Th17/Tc-17 Cells to TLR-2 and TLR-4 Ligands is a Feature of Multiple Sclerosis Patients at Higher Risk of Therapy Failure

Multiple Immune-Inflammatory and Oxidative and Nitrosative Stress Pathways Explain the Frequent Presence of Depression in Multiple Sclerosis

A-100 Selected pro-and anti-inflammatory cytokine serum concentrations in different clinical forms of multiple sclerosis

Immune-Inflammatory and Oxidative and Nitrosative Stress Biomarkers of Depression Symptoms in Subjects with Multiple Sclerosis: Increased Peripheral Inflammation but Less Acute Neuroinflammation

Decoding the inflammatory signature of the major depressive episode: insights from peripheral immunophenotyping in active and remitted condition, a case–control study

The alterations in CD4+Treg cells across various phases of major depression

Major Depression: An Immune-Inflammatory Disorder

T cell activation and deficits in T regulatory cells are associated with major depressive disorder and severity of depression

Mood Symptoms and Chronic Fatigue Syndrome Due to Relapsing-Remitting Multiple Sclerosis Are Associated with Immune Activation and Aberrations in the Erythron

Characterization of antigen-specific CD8+ memory T cell subsets in peripheral blood of patients with multiple sclerosis

CD300f immunoreceptor is associated with major depressive disorder and decreased microglial metabolic fitness

Cytokine Profile in Patients with Progressive Multiple Sclerosis and Its Association with Disease Progression and Disability

Multiple Sclerosis is Associated with High Levels of Circulating Dendritic Cells Secreting Pro-Inflammatory Cytokines

Major Depressive Disorder, Neuroticism, Suicidal Behaviors, and Depression Severity Are All Associated with Neurotoxic Immune Networks and Their Intricate Interactions with Metabolic Syndrome.

Increased memory Th17 cells in patients with neuromyelitis optica and multiple sclerosis.

Major depressive disorder, neuroticism, suicidal behaviors, and depression severity are associated with cytokine networks and their intricate interactions with metabolic syndrome

Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis

Study on memory T cell subsets in peripheral blood of patients with multiple sclerosis

T cell activation via the CD40 ligand and transferrin receptor and deficits in T regulatory cells are associated with major depressive disorder and severity of depression

Interleukin-17-secreting T Cells in Neuromyelitis Optica and Multiple Sclerosis During Relapse